Pfizer director Mortimer J. Buckley received a grant of 1,307.987 phantom stock units valued at approximately $37,500, according to an SEC insider-filing report published September 29, 2026. The reported transaction took place on September 25 and carried a stated price of $28.67 per unit. Pfizer trades under the ticker PFE.

The source identifies the transaction as an award or grant. That classification is central to reading the disclosure: it describes units received by the director, rather than an open-market purchase of Pfizer shares with personal funds.

What the SEC report shows

The SEC report names Buckley as a director of Pfizer and identifies the awarded security as phantom stock units. Multiplying the reported quantity by the stated price produces approximately $37,500, consistent with the value supplied in the summary.

The report also indicates that the transaction was not associated with a Rule 10b5-1 trading plan. That information describes the reported transaction; it does not establish whether Buckley has any separate trading arrangements.

September 25 is the transaction date, while September 29 is the publication date supplied for the filing report. The provided summary does not separately establish the filing's submission timestamp.

What the disclosure cannot establish

The supplied material does not detail vesting conditions, settlement provisions or restrictions attached to the phantom stock units. It also does not state Buckley's total holdings after the award or provide a broader history of his Pfizer transactions.

Analysis: The grant documents an award to a company director, but it provides limited evidence about his investment outlook. Treating it as a discretionary stock purchase would give the transaction a meaning that its reported classification does not support.

Nothing in the supplied summary establishes an effect on Pfizer's operating performance, valuation or share price.

What to watch

The underlying filing and any related award documents would be the relevant materials for checking settlement terms, vesting requirements and post-transaction holdings. Those details are not available in the supplied report.